Committees

Aims & Scope

The Mesenchymal Stromal Cell Committee strives to:

• Participate in the planning of the Roundtable Programs at the ISCT Annual Meeting and ISCT Regional Meetings and the review of submitted abstracts
• Review the status of the MSC field and compile position papers on the relevant scientific issues that must be addressed to advance or enable cellular therapies utilizing MSCs
• Foster international discussion about controversies in the MSC field and method/nomenclature standardization
• Offer educational opportunities to Early Stage Professionals (ESP) in the MSC field

Selected Publications

Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition (Cytotherapy. 2021 May; 23(5):368-372)
Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell and Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells (Cytotherapy. 2021 Dec; 23(12):1060-1063)

Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential (Cytotherapy. 2020 Nov; 22(11):602-605)

Improving mesenchymal stem/stromal cell potency and survival (Cytotherapy. 2020 Mar; 22(3):123-126)

Mesenchymal stromal cells for GVHD: A Trilogy. (Biology of Blood and Marrow Transplantation. 2020 Mar 07; DOI: https://doi.org/10.1016/j.bbmt.2020.02.023)

Mesenchymal stem versus stromal cells: International Society for Cellular Therapy Mesenchymal Stromal Cell committee position statement on nomenclature. (Cytotherapy. 2019 Oct; 21(10):1019-1024)

Perspectives of the International Society of Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi)(Cytotherapy. 2019 Aug;21(8):824-839)

Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers (Cytotherapy. 2019 Jul; 21(7):782-792)

Challenges for mesenchymal stromal cell therapies. (Sci Transl Med. 2019 Feb; 11(480))

Response to Nature commentary "Clean up this stem-cell mess. (Cytotherapy. 2019 Jan; 21(1):1-2)

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. Review.

A relativity concept in mesenchymal stromal cell manufacturing. (Cytotherapy. 2016 May;18(5):613-620.)

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. (Cytotherapy. 2016 Feb;18(2):151-159)

Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. (Cytotherapy. 2013 Sep;15(9):1054-1061)

MSCs: science and trials. (Nat Med. 2013 Jul;19(7):812.)

Mesenchymal stromal cells: misconceptions and evolving concepts. (Cytotherapy. 2013 Feb;15(2):140-145)

The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? (Cytotherapy. 2013 Jan;15(1):2-8)

Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. (Cell Stem Cell. 2012 Jan 6;10(1):9-10; author reply 10-1.)

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement (Cytotherapy 2006 Jan;8(4): 315-317)

The Committee

Members

Jacques Galipeau, MD
ISCT President (June 2020-June 2022)
University of Wisconsin-Madison
Madison, United States
Co-Chair, ISCT 2016 Annual Meeting

Mauro Krampera, MD, PhD
University of Verona
Verona, Italy

Manoj Lalu, MD, PhD, FRCPC
The Ottawa Hospital Research Institute
Ottawa, Canada
ISCT ESP Leadership Development Program

Katarina Le Blanc, MD, PhD
Karolinska University Hospital
Stockholm, Sweden
Co-Chair, ISCT 2017 MSC Series

Jan Nolta, PhD
University of California, Davis
Sacramento, United States
Co-Chair, ISCT 2018 MSC Pre-Conference Track

Dominique  Farge, MD, PhD
Hospital St-Louis
Paris, France

Edwin M. Horwitz, MD, PhD
Emory University School of Medicine
United States

Yufang Shi, PhD
Soochow University Institutes for Translational Medicine
Shanghai, China
Co-Chair, ISCT 2019 MSC Pre-Conference Track

Karin Tarte, PharmD, PhD
Rennes University Hospital
Rennes, France

Daniel Weiss, MD, PhD
University of Vermont
Burlington, United States

Francesco Dazzi, PhD
AstraZeneca
Great Abington, United Kingdom

Nisha Durand, PhD
Mayo Clinic
Jacksonville, United States
ESP Leadership Development Program

Michael Creane, PhD
University of Galway
Galway, Ireland
ESP Leadership Development Program